Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs worldwide. More than 50% of the adult Danish population redeemed at least one prescription of an NSAID during 1997-2005 and 29.6 million adults in the USA used NSAIDs on a regular basis in 2010. 1, 2 Over the last decade, evidence of a cardiovascular risk associated with use of NSAIDs has emerged. The selective cyclooxygenase-2 (COX-2) inhibitors, and to a lesser extent the non-selective NSAIDs, have been associated with cardiovascular adverse events, such as myocardial infarction, stroke, and heart failure in randomized and observational studies. [3] [4] [5] [6] [7] [8] [9] [10] [11] Cardiac arrest is the ultimate adverse drug event, and though it is closely linked to ischaemic disease and cardiovascular morbidity, the association between NSAIDs and cardiac arrest has never been investigated. [12] [13] [14] Currently, there is no research pertaining to NSAIDs pro-arrhythmic effects regarding ventricular arrhythmias as isolated events; however, an association with NSAIDs and sudden cardiac death as part of a composite endpoint with myocardial infarction has been observed. 5, 15 Consequently, it remains to be established, whether use of NSAIDs is associated with cardiac arrest. This prompted us to conduct an observational case-time-control study using data from the Danish nationwide registries to investigate the association between use of NSAIDs and risk of out-of-hospital cardiac arrest (OHCA).
Methods

Study design
The association between NSAID use and cardiac arrest was explored in the case-time-control design, an acknowledged pharmacoepidemiologic method designed to evaluate brief exposures with acute effects. 16 The design has been validated and used in several previous studies. [16] [17] [18] [19] The case-time-control design is an extended case-crossover design where each individual serves as both case and their own control in two different time-periods. The 'case period' precedes outcome, and the 'control period' of same length precedes the case period. Exposure to NSAIDs 30 days before cardiac arrest (case period) was assessed and compared with exposure to NSAIDs in a preceding 30-day period where the individual did not experience an event (control period). A 30-day washout period separated case and control period to eliminate possible carry-over effects. A major advantage of the case-crossover design is the elimination of unmeasured confounding from characteristics that remain stable over time (e.g. comorbidity). Although a case-crossover design is vulnerable to changes in prevalence of exposure over time, a case-time-control design incorporates data from a control group selected from the general population to adjust for possible time-variant biases related to exposure. The prevalence of exposure to NSAIDs in Denmark could have been influenced by changes in prescription patterns over time due to safety alerts regarding the COX-2 selective inhibitors. Consequently, we performed a case-time-control analysis, consisting of two separate case-crossover analyses for cardiac arrest cases and the control group, respectively. Thus, the control group is used only to adjust for changes in prescribing patterns in the background population. Controls were assigned a fictive date of cardiac arrest according to the case they were matched upon. Only individuals with differing exposure in case and control period contributed to the final analysis. Because median treatment duration in Denmark for all types of NSAIDs is between 13 and 29 days and previous studies have observed enhanced cardiovascular risk associated with less than 30 days of treatment with NSAIDs, the case period was defined to 30 days. 1, 20, 21 Using the odds ratio (OR) from the casecrossover analysis of the control group as a measurement of time trends in exposure, the case-time-control OR is calculated by dividing the OR from cases by the OR from controls.
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Data sources 
Study patients
Via the Danish Cardiac Arrest Registry, we identified all persons with OHCA during 2001-10, who on 1 January 1997 were aged > _ 10 years. From the Danish Patient Registry, four controls matched on age and sex were selected for every case by using the greedy matching algorithm, a method used and described previously. 17 As previously done, information on comorbidity in the cardiac arrest population was obtained via discharge diagnoses from admissions up to 5 years before event, and concomitant pharmacotherapy was identified from redeemed prescriptions up to 90 days before event. 17 As the diagnosis code of diabetes has a low sensitivity in the Danish registries, diabetes was identified based on redemption of a prescription for a glucose-lowering drug within 180 days before cardiac arrest, as done previously. 25 
Exposure
We detected all redeemed prescriptions for NSAIDs divided into the most commonly used NSAIDs in Denmark: non-selective NSAIDs (diclofenac, naproxen, and ibuprofen), COX-2 selective inhibitors (rofecoxib and celecoxib), and other. To determine whether a patient was using NSAIDs during the case or control period, we identified dates when prescriptions were redeemed and then calculated duration of treatment by dividing the number of tablets in the prescription of interest by daily dosage. As information about daily dosage is not included in the registries, daily dosage was estimated by calculating mean dosages from up to five consecutive prescriptions before the prescription of interest. If only one prescription was identified, the minimal recommended daily dosage was used as daily dosage. This method has been used in several papers and has been described in detail previously.
1,26
We did not have information on over-the-counter medication; however, the only NSAID available in Denmark without prescription is ibuprofen sold only in low dosage (200 mg) and small packages (max 20 tablets).
For further details regarding Anatomical Therapeutic Chemical Classification codes, see Supplementary material online, Table S1 .
Outcome
Our primary endpoint was OHCA. As cause of cardiac arrest is not registered in the Danish Cardiac Arrest Registry, presumed cause of cardiac arrest was classified using discharge diagnoses from The Danish Patient Registry and death certificates from The National Causes of Death Registry. A presumed cardiac cause of cardiac arrest was defined as an event with diagnosis code covering a known cardiac disease, unknown disease, or unexpected collapse according to the Utstein template. 23, 27 Other medical disorders were considered non-cardiac causes, as was trauma, drug overdose, attempted suicide, and violent attack. 
Statistical methods
Differences in baseline characteristics in the cardiac arrest population between NSAID users versus non-users and among those using specific types of NSAIDs were tested using the v 2 test for binary variables and the Wilcoxon-Mann-Whitney test for continuous variables. Trends in drug use over time were tested with the Cochran-Armitage trend test. The association between NSAID use and cardiac arrest was tested by conditional logistic regression in case-time-control models. We tested for confounding by acute disease exacerbation by excluding individuals admitted up to 60 days before cardiac arrest and excluding individuals with cancer, respectively. This was done since the case-time-control method does not eliminate confounding from characteristics that change between case and control period and lack of clinical data in the Danish registries makes control for time-varying variables impossible.
All statistical analyses were performed using SAS version 9.2 (SAS institute Inc., NC, USA). A two-sided P-value < 0.05 was considered significant. 
Ethics
Results
We identified 28 947 persons with OHCA during 2001-10 and matched 115 788 controls with cases on age and sex. Within the 30-day case period, 3376 (11.7%) persons were treated with an NSAID. Compared with non-users, NSAID users were more often women, had generally less cardiovascular diseases, such as ischaemic heart disease, myocardial infarction, and heart failure, but were more likely to have cancer and rheumatic diseases (P for all <0.05, Table 1 ). Moreover, NSAID users were more often treated with morphine, diuretics, and psychiatric medication (P for all < 0.05).
Ibuprofen was the most commonly prescribed NSAID followed by diclofenac comprising 51.0% and 21.8% of total NSAIDs, respectively ( Table 2) . Overall, baseline characteristics did not differ substantially within groups of users of non-selective NSAIDs (ibuprofen, diclofenac, and naproxen) and COX-2 selective inhibitors (rofecoxib and celecoxib), respectively. However, baseline characteristics did differ between groups; non-selective NSAIDs were associated with younger age, male gender, and lower prevalence of heart failure and cardiac arrhythmias in comparison with users of the COX-2 selective inhibitors. Figure 1 shows use of NSAIDs over time in the cardiac arrest population (A) and in the control group (B) during 2001-10. Overall, the utilization patterns between cases and controls were alike with a stable proportion of users of any NSAID of approximately 12% annually for cases (P for trend = 0.65) and 10% annually for controls (P for trend <0.0001).
The main results from the case-time-control analysis are depicted in Figure 2 . Use of any NSAID was associated with a significantly increased risk of cardiac arrest, OR 1.31 (95% confidence interval (CI) 1.17-1.46). Likewise, use of non-selective NSAIDs was associated with increased risk of cardiac arrest, OR 1.32 (95% CI 1.18-1.48), whereas no risk was significantly associated with use of the COX-2 selective inhibitors, OR 1.19 (95% CI 0.89-1.59).
The risk of cardiac arrest associated with use of the most common types of NSAIDs is depicted in Figure 3 . Use of ibuprofen was significantly associated with an increased risk of cardiac arrest, OR 1.31 (95% CI 1.14-1.51) as was use of diclofenac, OR 1.50 (95% CI 1.23-1.82). Naproxen use was not significantly associated with cardiac arrest, and we did not find any significant associations between cardiac arrest and use of COX-2 selective inhibitors, rofecoxib and celecoxib.
Effect modification by age and sex was tested by stratified analyses, see Supplementary material online, Figures S1 and S2 .
For more details regarding the distribution of cardiac arrest subjects in case and control period, respectively, and respective OR from cases and control group, see Supplementary material online, Table S2 . Figure S3 . Including only subjects with a presumed cardiac cause of cardiac arrest did not change the results either: ibuprofen OR 1.29 (95% CI 1.10-1.51) and diclofenac OR 1. 45 (95% CI 1.18-1.87), Supplementary material online, Figure S4 . Lastly, exclusion of subjects with cancer produced similar results; ibuprofen OR 1.33 (95% CI 1.15-1.54); diclofenac OR 1.50 (1.21-1.85). The association between cardiac arrest and naproxen, celecoxib, and rofecoxib remained insignificant in all sensitivity analyses.
Sensitivity analyses
Discussion
In this nationwide case-time control study, we found that use of nonselective NSAIDs was associated with an increased risk of OHCA. The result was primarily driven by an increased risk of cardiac arrest in ibuprofen and diclofenac users. We found no significant association between cardiac arrest and use of the COX-2 selective inhibitors, rofecoxib and celecoxib, nor with the unselective NSAID naproxen. The results were verified in multiple sensitivity analyses, including the exclusion of presumed non-cardiac causes of cardiac arrest, and using different definitions of exposure periods.
To our knowledge, this is the first study to investigate the association between NSAIDs and OHCA. Currently, no research relating to NSAIDs' pro-arrhythmic effects with regard to ventricular arrhythmias has been published; consequently, we compared our findings in relation to studies with other cardiovascular endpoints, such as myocardial infarction and cardiovascular death. However, although cardiac arrest is a combined endpoint, it is closely related to cardiovascular morbidity, particularly ischaemic heart disease, which has been observed in more than 60% of all OHCA and 80% of sudden cardiac deaths. [12] [13] [14] 28 In this study, short-term use of ibuprofen was associated with an increased risk of cardiac arrest, OR 1.31. In two recent meta-analyses of randomized trials, ibuprofen was also reported to be associated with a substantial cardiovascular hazard: Bhala et al. 4 reported a twofold increased risk of major coronary events when using ibuprofen compared with placebo and a non-significant increased risk of vascular death and death from any cause; Trelle et al. 7 reported a more than 30% increased risk of several cardiovascular endpoints, such as myocardial infarction, cardiovascular death, and death from any cause, comparing ibuprofen with placebo. As few randomized trials of ibuprofen exist, the meta-analyses lack statistical power regarding ibuprofen. Moreover, the trials were investigating high-dose treatment only with daily use of 2400 mg ibuprofen, which is considerably higher than dosages used in daily practice. 1 Even though the case-time-control method eliminates confounding from stable characteristics, such as cardiac comorbidity and concomitant pharmacotherapy, we cannot fully exclude confounding by indication related to fluctuations in disease severity that could lead to a change in NSAID use. Nonetheless, our findings indicate a harmful association between ibuprofen and cardiac arrest and support the emerging evidence of an unfavourable association between ibuprofen and cardiovascular safety. We found that diclofenac was associated with an increased risk of cardiac arrest, OR 1.50, which concurs with findings in several other studies: Bhala et al. found a significantly increased risk of major coronary events and vascular death of 70% and 65%, respectively, and Trelle et al. 4, 7 reported a significantly increased risk of cardiovascular death with a rate ratio of four. Again, the composite nature of cardiac arrest entails careful interpretation, yet our results add to the accumulating evidence that diclofenac is associated with increased cardiovascular risk. Notably, we found no significant association between cardiac arrest and the COX-2 selective inhibitors, rofecoxib and celecoxib. Several randomized clinical trials found a dose-dependent increased cardiovascular hazard with rofecoxib treatment, which led to a complete withdrawal of rofecoxib from the market in 2004.
3,9,10 Studies on celecoxib have had more ambiguous findings, and although a large randomized clinical trial found a doserelated risk of death from cardiovascular causes, acute myocardial infarction, stroke, and heart failure, other studies, including the meta-analysis by Trelle et al., 6, 7 found no such risk. However, when grouping the COX-2 selective inhibitors, Bhala et al. 4 found a significant increased risk of vascular death and death from any cause. Rofecoxib and celecoxib are seldom used in Denmark, especially after 2006 when rofecoxib was withdrawn from the market, and this combined with a hard endpoint (cardiac arrest) entailed relatively few events in our study and possibly low statistical power. Thus, in light of previous research, our findings of an apparent safety regarding cardiac arrest and use of COX-2 selective inhibitors should be interpreted with caution. Lack of statistical power applies to naproxen as well. As naproxen is rarely used in Denmark, there were few events and a wide CI. Though the OR point estimate suggests an association with cardiac arrest similar to what we find in ibuprofen and diclofenac users, the study has insufficient power to examine the importance of naproxen.
Limitations
The main limitation of the study is inherent in the observational nature of the analyses. The treatment allocation is not randomized and the study reports only associations and therefore any conclusion on causality should be made with caution. Information on drug use originates from the Danish pharmacies and we have no information regarding compliance; however, as drug expenses are only partially reimbursed by Danish Health Care authorities, we assume that non-compliance had little influence on our results. In addition, non-compliance would affect the results towards null and thus reduce the association between exposure and outcome.
Moreover, we do not have information on use of over-the-counter drugs. In Denmark, ibuprofen is the only NSAID sold as an over-thecounter drug (since 1 November 2001) and accounts for 30% of total ibuprofen sales during 1999-2012. It is sold only in 200 mg dosages and in small packages (maximum 30 tablets per package). 29 Using prescription data without information on over-the-counter ibuprofen entails a risk of underestimating the true exposure prevalence. However, in our study, the exposure misclassification should be equally distributed in both case-and control period. Moreover, a study quantifying the effect of missing information on over-the-counter NSAID found the effect on study validity to be almost negligable. 30 Acetylsalicylic acid is also sold as an over-the-counter drug in Denmark, but since 2002 more than 80% of low-dose acetylsalicylic acid has been dispensed by prescription and the influence on our results should be minimal. 29 Lastly, the determination of treatment duration is an approximation, however, used in numerous papers before.
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Conclusion
In a nationwide cohort of persons with OHCA, we found that shortterm treatment with non-selective NSAIDs, particularly ibuprofen and diclofenac, was associated with an increased early risk of cardiac arrest. We found no association between cardiac arrest and use of the COX-2 selective inhibitors, rofecoxib and celecoxib, nor the non-selective NSAID naproxen. Our findings support the accumulating evidence of an unfavourable cardiovascular risk profile associated with use of the non-selective NSAIDs. This calls for special awareness in order to balance risks against benefits in treatment with NSAIDs.
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